Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01640691
Recruitment Status : Unknown
Verified July 2012 by Adimmune Corporation.
Recruitment status was:  Recruiting
First Posted : July 16, 2012
Last Update Posted : July 16, 2012
Information provided by (Responsible Party):
Adimmune Corporation

Brief Summary:
The objectives of this single arm study are to evaluate the immune response and safety profiles of two injections of an inactivated whole-virion vaccine containing aluminum hydroxide adjuvant, AdimFlu-W (H5N1), against influenza A (H5N1) in healthy adults.

Condition or disease Intervention/treatment Phase
Pandemic Influenza Biological: Pandemic Influenza Vaccine (H5N1) Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Clinical Study to Evaluate the Immunogenicity and Safety of Pandemic Influenza Vaccine, AdimFlu-W (H5N1), in Healthy Adults
Study Start Date : July 2012
Estimated Primary Completion Date : April 2013

Resource links provided by the National Library of Medicine

Intervention Details:
  • Biological: Pandemic Influenza Vaccine (H5N1)

    Inactivated whole-virion vaccine

    1. Administration route: Intramuscular Injection
    2. Dosing schedule: 2 injections - at Day 1 and Day 22 separately
    3. Dose(s): Each dose (0.5 mL) contains the 15 mcg hemagglutinin (HA) of influenza A (A/Vietnam/1194/2004)
    Other Name: AdimFlu-W (H5N1) Pandemic Influenza Vaccine

Primary Outcome Measures :
  1. Immunogenicity Endpoint: hemagglutination inhibition (HAI) titer and microneutralization (MN) titer [ Time Frame: At Day 43 (21 days after the second dose). ]

    The primary immune response endpoint is to evaluate the seroconversion rate (SCR) in terms of HAI assays at Day 43 (21 days after the second dose).The secondary HAI endpoints are defined as following:

    1. SCR for the first vaccination, at Day 22.
    2. Seroprotection rates (SPR) for each vaccination, at Day 22 and 43.
    3. The geometric mean fold rise (GMFR) for each vaccination, at Day 22 and 43.

    The supportive immunogenicity endpoints of MN antibodies are SCRs, SPRs and GMFRs at Day 22 and 43.

Secondary Outcome Measures :
  1. The secondary objective is to evaluate the safety and tolerability profiles including the presence or absence of the pre-specified reactogenicity events and other serious/non-serious adverse events after vaccination. [ Time Frame: At 4 weeks after two doses of study vaccine, 4 weeks apart. Reactogenicity will be recorded for 7 days after each vaccination. ]
    Safety data will consist of reactogenicity, serious and non-serious adverse events. Reactogenicity events are pre-specified adverse events systematically recorded for 7 days after each vaccination.The events included fever (≥38.0°C), runny nose or nasal congestion, cough, sore throat, muscle aches, headache, vomiting, nausea and malaise. Furthermore, the local (injection site) reactions were also evaluated, including soreness/pain, swelling, redness, ecchymosis and limitation of arm motion.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • A male or non-pregnant female (as indicated by a negative urine pregnancy test immediately on the day prior to first vaccine administration) between 20 to 60 years of age at the time of the first vaccination. Women of childbearing potential agree to practice highly effective birth control throughout the study (from Screening to Month 3).
  • Subjects are free of obvious health problems as judged by investigator (established by medical history and physical examination) before entering the study.
  • Subject is physically and mentally capable of participating in the study and willing to adhere to study procedures to complete all elements of the study diary.
  • Subjects provide signed informed consent after receiving a detailed explanation of the study protocol prior to any study procedures.

Exclusion Criteria:

  • Medical history of physician-confirmed infection with an H5N1 virus or a history of vaccination with an H5N1 influenza vaccine.
  • Subject is at high risk of contracting H5N1 influenza infection (e.g. poultry workers).
  • Has received any other licensed vaccines within 2 weeks for inactivated vaccines or 4 weeks for live vaccines prior to enrollment in this study.
  • Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Subject has used oral or parenteral steroids, high-dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) or other immunosuppressive or cytotoxic drugs within 30 days preceding the first dose of study vaccine.
  • Subject has received a blood transfusion or immunoglobulins within 90 days prior to first dose of study vaccine, or planned administration of any blood products during the study period.
  • Subject has a known allergy to eggs or other components of the study vaccine.
  • Subject has a history of severe allergic reactions or anaphylaxis.
  • Subject has a history of Guillain-Barré Syndrome.
  • Subject has an acute illness or temperature greater than 38.0 degrees Celsius by any method within 3 days prior to each vaccination.
  • Subject has confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus (HIV) infection.
  • Subject has a rash, dermatologic condition or tattoos which may interfere with injection site reaction rating.
  • Evidence of substance (alcohol or drug) abuse or of neurological or psychiatric diagnoses which, even if clinically stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.
  • Subjects with abnormal laboratory results at screening:(1) ALT or AST > or = 1 x upper limit of normal (ULN). (2) Creatinine > or = 1 x ULN. (3) Any significant laboratory abnormality as judged by the investigator
  • Females are known pregnancy or a positive urine beta-human chorionic gonadotropin test result prior to the first study vaccine dose, or are lactating or nursing.
  • Subject has any other condition that disqualifies his/her participation in the study in the opinion of the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01640691

Contact: Wendy Tsen

National Cheng Kung University Hospital Recruiting
Tainan, Taiwan
Sponsors and Collaborators
Adimmune Corporation
Principal Investigator: Chih-Jen Chang, MD National Cheng-Kung University Hospital

Responsible Party: Adimmune Corporation Identifier: NCT01640691     History of Changes
Other Study ID Numbers: FLUW001A
First Posted: July 16, 2012    Key Record Dates
Last Update Posted: July 16, 2012
Last Verified: July 2012

Keywords provided by Adimmune Corporation:
pandemic influenza
pandemic influenza vaccine

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Immunologic Factors
Physiological Effects of Drugs